This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day

CAMBRIDGE, Mass., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today its alliance with The FH Foundation in observance of the annual Familial Hypercholesterolemia (FH) Awareness Day.

"We support The FH Foundation in their mission, and are committed to increasing awareness about familial hypercholesterolemia, a very serious and often undiagnosed disease that effects patients and their families," said Marc D. Beer, Chief Executive Officer of Aegerion.

Familial hypercholesterolemia (FH) is a serious, genetic condition, and one of the most common inherited disorders. A person with FH is unable to remove the cholesterol that our bodies naturally produce and as a result, their blood cholesterol levels increase significantly. There are two forms of the disease: in heterozygous FH (HeFH), the genetic defect causing the impairment is inherited from one parent; and in homozygous FH (HoFH), the defect is inherited from both parents. HoFH is the most severe form of the disorder.

To learn more about familial hypercholesterolemia, visit or see Dr. Pam Morris, a lipidologist at the University of South Carolina, discuss the disorder on " The Balancing Act."

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit .
CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy
         Manager, Investor Relations & Public Relations

Aegerion Pharmaceuticals, Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs